Table. 1 Baseline characteristics of EDP vs non-EDP groups (n = 10), in which safety, bNAb concentrations, and administration times were compared
Characteristic | Overall (N = 10) | CAP256V2LSa + VRC07523.LSa (20 mg/kg SC/20 mg/kg SC) one dose (N = 5) | CAP256V2LS + VRC07523.LS (20 mg/kg SC/20 mg/kg SC) one dose (N = 5) | |
|---|---|---|---|---|
Age (years) | 27.5 (24.0–30.0) | 27.0 (25.0–28.0) | 28.0 (24.0–30.0) | |
Sex | Female | 10 (100%) | 5 (100%) | 5 (100%) |
Ethnicity | African | 10 (100%) | 5 (100%) | 5 (100%) |
Weight (kg) | 68.5 (64.8–73.6) | 71.9 (57.1–83.5) | 65.0 (64.8–72.6) | |
Height (m) | 1.6 (1.5–1.6) | 1.6 (1.6–1.6) | 1.5 (1.5–1.6) | |
BMI | 27.6 (26.4–29.2) | 27.4 (23.2–33.0) | 27.8 (27.3–28.4) | |
Hemoglobin (g/dL) | 13.2 (12.1–13.9) | 13.4 (13.0–14.6) | 12.1 (11.5–13.3) | |
Creatinine (μmol/L) | 60.5 (55.0–63.0) | 63.0 (62.0 – 64.0) | 55.0 (51.0–60.0) | |
Aspartate aminotransferase (IU/L) | 23.5 (21.0–28.0) | 23.0 (18.0–23.0) | 28.0 (24.0–32.0) | |
Alanine aminotransferase (IU/L) | 19.0 (17.0–20.0) | 19.0 (17.0–20.0) | 20.0 (19.0–28.0) |
